Curcumin for Inflammatory Bowel Disease

Verdict: Promising add-on for colitis, not Crohn's

For ulcerative colitis, oral curcumin shows preliminary but consistent benefit as an add-on to standard mesalamine therapy, roughly doubling the odds of clinical remission. For Crohn's disease, the evidence does not show it works, so it should never replace prescribed IBD medication.

B 🟡 B Preliminary Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The grade reflects a sharp split by IBD subtype. Three meta-analyses of adjunctive curcumin in ulcerative colitis converge on a real signal for clinical remission added to 5-ASA: relative risks of about 2.0 to 2.3 (PMID 35091013, 39612780, 40196017), anchored by the Lang 2015 trial showing remission of 53.8% vs 0% (PMID 25724700). The AGA conditionally suggests curcumin as an add-on for mild-to-moderate UC, and Mayo and Cleveland Clinic agree it may reduce inflammation.

It stays at preliminary (not strong) because the evidence base is thin and uneven. Heterogeneity is high (I2=80% in PMID 39612780), endoscopic remission generally fell short of significance even where symptoms improved, and the anchor trial's confidence interval is enormous (OR 42, 95% CI 2.3-760, n=50), reflecting small samples and non-standardized doses and formulations.

For Crohn's disease the verdict is clearly negative: the 2025 pooled analysis found no superiority over placebo (PMID 40196017), and the lone positive result is a single small Japanese Theracurmin trial (40% vs 0%, n=30; PMID 32412598). NIH/NCCIH says the evidence is not yet definitive, EFSA rejected curcumin health claims, and regulators flag liver-injury risk with high-bioavailability products, so curcumin is at most a supervised adjunct, not a treatment.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.65
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
B · Published with Warning
Confidence
78%
Broadly consistent
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L5 Clinical bodiesAuthoritative stance
0.46
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.65
L11 AI re-checkIndependent read
0.65
L2 PubMedPrimary literature
0.85
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.649
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (6)L2 · primary research & systematic reviews

Curcumin for the clinical treatment of inflammatory bowel diseases: a systematic review and meta-analysis of placebo-controlled randomized clinical trials
PMID: 40196017 2025 統合分析 n = 13
Finding: UC: clinical response significantly improved vs placebo (RR 2.04, 95% CI 1.30-3.20, p=0.002); clinical remission trend (RR 3.04, p=0.07); endoscopic remission near-significant (RR 3.81, p=0.06). CD: no superiority over placebo for clinical or endoscopic remission. Adverse events and withdrawals comparable to placebo.
Effect size: [object Object]
View on PubMed
Safety and efficacy of curcumin in the treatment of ulcerative colitis: An updated systematic review and meta-analysis of randomized controlled trials
PMID: 39612780 2024 統合分析 n = 482
Finding: Adjunctive curcumin significantly improved clinical remission (RR 2.33, 95% CI 1.25-4.34, p=0.008, I2=80%); clinical improvement (RR 1.93, 95% CI 1.10-3.36, p=0.02); endoscopic improvement (RR 1.76, 95% CI 1.12-2.77, p=0.01). Endoscopic remission non-significant trend (RR 4.17, 95% CI 0.63-27.71, p=0.14). No serious adverse events.
Effect size: [object Object]
View on PubMed
Efficacy and safety of adjuvant curcumin therapy in ulcerative colitis: A systematic review and meta-analysis
PMID: 35091013 2022 統合分析 n = 385
Finding: Adjuvant curcumin effective for inducing clinical remission (RR 2.10, 95% CI 1.13-3.89). Clinical improvement (RR 1.62, 95% CI 1.00-2.61) and endoscopic outcomes (RR 4.17, 95% CI 0.63-27.71) not statistically significant. No severe adverse effects.
Effect size: [object Object]
View on PubMed
Highly Bioavailable Curcumin Derivative Ameliorates Crohn's Disease Symptoms: A Randomized, Double-Blind, Multicenter Study
PMID: 32412598 2020 RCT (double-blind) n = 30
Finding: Clinical remission at week 12: 40% (Theracurmin 8/20) vs 0% (placebo 0/10), p=0.020; significant CDAI reduction by week 12 (p=0.005); endoscopic remission 15% vs 0%; significant anal lesion healing at week 8 (p=0.017). No serious adverse events. Only modern RCT showing benefit in CD; small sample limits generalizability.
View on PubMed
Curcumin therapy for ulcerative colitis remission: systematic review and meta-analysis
PMID: 32772752 2020 統合分析
Finding: Curcumin can help induce remission in UC subjects through anti-inflammatory and antioxidant effects; supports adjunctive role with 5-ASA. Quantitative pooled effect size not extractable from abstract; heterogeneity in dose/route flagged as limitation.
🟠 Limited quality
View on PubMed
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial (Lang et al.)
PMID: 25724700 2015 RCT (double-blind) n = 50
Finding: Clinical remission 53.8% (curcumin) vs 0% (placebo), p=0.01, OR 42 (95% CI 2.3-760); clinical response (>=3-point SCCAI drop) 65.3% vs 12.5%, OR 13.2 (95% CI 3.1-56.6), p<0.001; endoscopic remission 38% vs 0%, OR 20.7 (95% CI 1.1-393), p=0.043. Most-cited modern UC trial; pre-2020 but anchors all subsequent meta-analyses.
Effect size: [object Object]
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4b EU EFSA
Cautious
the Panel established an ADI for curcumin of 3 mg/kg bw/day source↗
L4c UK NHS
Cautious
Avoid turmeric and curcumin in individuals with bile duct obstruction, cholangitis, liver disease, gallstones, or any biliary disease. source↗
L4d TW TFDA / 衛福部
Cautious
薑黃素每人每日攝取量為每公斤體重0~3毫克,每日不超過200毫克為宜 source↗
L4e WHO
Neutral
Rhizoma Curcumae Longae source↗
L5a NIH Office of Dietary Supplements
Cautious
We don't know enough to definitively conclude if turmeric or curcumin is beneficial for any health purposes. source↗
L5b Mayo Clinic
Cautious
may help reduce inflammation source↗
L5c Cleveland Clinic
Cautious
may help reduce inflammation in ulcerative colitis source↗
L5e Specialty Society (condition-mapped)
Neutral
In adult outpatients with mild-moderate UC, the AGA suggests adding curcumin to standard mesalamine therapy for induction of remission source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬6 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-ibd-INT-curcumin-001 繁體中文版 →